Porownywarka

Thymogen vs LL-37 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

ThymogenLL-37

Udostępnij porównanie peptydów

Wlasciwosc	Thymogen	LL-37
Kategoria	Odporność	Odporność
Znany tez jako	EW Dipeptide, Glu-Trp, L-Glutamyl-L-Tryptophan, Oglufanide	Cathelicidin, CAP18
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Source-reported: approved in Russia for clinical immunomodulation; used since 1990. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Immune modulation, T-cell support, immune aging	Antimicrobial, infections, biofilm disruption, wound healing
Jak dziala	The source describes an immunomodulatory hypothesis rather than a fully defined target. Reported experimental findings associate L-Glu-L-Trp with T-cell differentiation, peptide-MHC recognition, altered intracellular cyclic nucleotides, and increased neutrophil chemotaxis and phagocytosis. It also notes reported DNA-level gene-expression effects. The initiating molecular mechanism remains unresolved, and the source presents immune effects as more documented than the gene-expression claims.	LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils.
Typowe dawkowanie	1-2 capsules (10-20 mg) daily · 1-2x daily, before meals	100-200 mcg daily · Once daily
Dawkowanie z badań	10-20 mg daily oral · 30-day courses with 2-3 month breaks · Oral capsules, also available as nasal spray in some regions	100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical
Typowy czas trwania	30-day courses with 2-3 month breaks	Variable by protocol
Podanie	Oral capsules; nasal spray availability is reported for some regions.	Subcutaneous injection or topical
Timing	Morning, before meals With or without food	Morning With or without food
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Generally well-tolerated (Source-reported; the source says individual responses may vary with dose, duration, and personal health factors.) No significant side effects reported in clinical use (This is a source report, not an independently verified safety conclusion.) Rare allergic reactions possible (Source-reported possibility.) +1 więcej Individual intolerance to components (Source-reported possibility.)	Injection-site reactions (Reported as common in the source.) Skin toxicity (Source examples include ulcers and burning.) Allergic reactions (Reported by the source without severity grading.) +4 więcej Histamine release (Source flags caution for MCAS or histamine sensitivity.) Possible contribution to autoimmune conditions (Reported as a potential concern, not established causality.) High-dose toxicity concerns (Source flags concern at higher doses.) Limited long-term safety data (Source notes uncertainty around longer-term safety.)
Podsumowanie researchu	The source describes a 2000 Anisimov Biogerontology experiment in which the dipeptide was given to rats. It reports associations with greater maximum lifespan, lower tumor incidence, and an approximately 3.4-fold reduction in blood cancers versus controls; this was not a human trial. It characterizes the broader clinical and laboratory literature as predominantly older Russian-language work linked to the original developers, with limited independent Western replication. According to the source, contemporary external randomized controlled trials have not confirmed immune or anti-aging claims to current evidence standards.	The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings.
Referencje	Źródło Źródło +1 więcej Źródło	Peptibase peptides Peptibase peptides +3 więcej Peptibase peptides Peptibase peptides Peptibase peptides
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Thymogen

LL-37

Kategoria

Odporność

Znany tez jako

EW Dipeptide, Glu-Trp, L-Glutamyl-L-Tryptophan, Oglufanide

Cathelicidin, CAP18

Zatwierdzony przez FDA

Nie

Status kliniczny

Source-reported: approved in Russia for clinical immunomodulation; used since 1990.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Immune modulation, T-cell support, immune aging

Antimicrobial, infections, biofilm disruption, wound healing

Jak dziala

The source describes an immunomodulatory hypothesis rather than a fully defined target. Reported experimental findings associate L-Glu-L-Trp with T-cell differentiation, peptide-MHC recognition, altered intracellular cyclic nucleotides, and increased neutrophil chemotaxis and phagocytosis. It also notes reported DNA-level gene-expression effects. The initiating molecular mechanism remains unresolved, and the source presents immune effects as more documented than the gene-expression claims.

LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils.

Typowe dawkowanie

1-2 capsules (10-20 mg) daily · 1-2x daily, before meals

100-200 mcg daily · Once daily

Dawkowanie z badań

10-20 mg daily oral · 30-day courses with 2-3 month breaks · Oral capsules, also available as nasal spray in some regions

100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical

Typowy czas trwania

30-day courses with 2-3 month breaks

Variable by protocol

Podanie

Oral capsules; nasal spray availability is reported for some regions.

Subcutaneous injection or topical

Timing

Morning, before meals

With or without food

Morning

With or without food

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Generally well-tolerated (Source-reported; the source says individual responses may vary with dose, duration, and personal health factors.)
No significant side effects reported in clinical use (This is a source report, not an independently verified safety conclusion.)
Rare allergic reactions possible (Source-reported possibility.)

+1 więcej

Individual intolerance to components (Source-reported possibility.)

Injection-site reactions (Reported as common in the source.)
Skin toxicity (Source examples include ulcers and burning.)
Allergic reactions (Reported by the source without severity grading.)

+4 więcej

Histamine release (Source flags caution for MCAS or histamine sensitivity.)
Possible contribution to autoimmune conditions (Reported as a potential concern, not established causality.)
High-dose toxicity concerns (Source flags concern at higher doses.)
Limited long-term safety data (Source notes uncertainty around longer-term safety.)

Podsumowanie researchu

The source describes a 2000 Anisimov Biogerontology experiment in which the dipeptide was given to rats. It reports associations with greater maximum lifespan, lower tumor incidence, and an approximately 3.4-fold reduction in blood cancers versus controls; this was not a human trial. It characterizes the broader clinical and laboratory literature as predominantly older Russian-language work linked to the original developers, with limited independent Western replication. According to the source, contemporary external randomized controlled trials have not confirmed immune or anti-aging claims to current evidence standards.

The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings.

Referencje

Źródło Źródło

+1 więcej

Źródło

Peptibase peptides Peptibase peptides

+3 więcej

Peptibase peptides Peptibase peptides Peptibase peptides

Pełny profil

Zobacz szczegóły